Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 805

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 805
---
 Combination or 12 months from the closing of the IPO). Further, Convertible Promissory Notes are also contingently exercisable upon the consummation of the initial Business Combination. For EPS purpose, the warrants and notes are anti-dilutive since they would generally not be reflected in basic or diluted EPS until the contingency is resolved. For the three months ended March 31, 2025 and 2024, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income per ordinary share is the same as basic earnings per ordinary share for the periods presented.

The net income per share presented in the consolidated statements of operations is based on the following:

|                                                   |     | ThreemonthsendedMarch 31,2025 |          |   |     | ThreemonthsendedMarch 31,2024 |          |   |
|:--------------------------------------------------|:----|:------------------------------|:---------|:--|:----|:------------------------------|---------:|:--|
| Net (loss)/income                                 |     | $                             | (194,603 | ) |     | $                             |  264,330 |   |
| Accretion of temporary equity to redemption value |     |                               | (124,162 | ) |     |                               | (803,885 | ) |
| Net loss including accretion of temporary equity  |     | $                             | (318,765 | ) |     | $                             | (539,555 | ) |

|                                                                |     | For the Three Months EndedMarch 31, 2025 |         |   |     |                           |           |   |     | For the Three Months EndedMarch 31, 2024 |           |   |     |                           |           |   |
|:---------------------------------------------------------------|:----|:-----------------------------------------|--------:|:--|:----|:--------------------------|----------:|:--|:----|:-----------------------------------------|----------:|:--|:----|:--------------------------|----------:|:--|
|                                                                |     | RedeemableCommonStock                    |         |   |     | Non-RedeemableCommonStock |           |   |     | RedeemableCommonStock                    |           |   |     | Non-RedeemableCommonStock |           |   |
| Basic and diluted net income